MUCOBOOST: all Phase 1 vaccinations have been administered
A key milestone before Phase 2 of LVT-001
All volunteers in the Phase 1 MUCOBOOST trial (NCT06821126) have received LVT-001, our first product from LVT-NEXUS.
This phase is designed to evaluate the safety of our intranasal vaccine against COVID-19 at three different dose levels.
Phase 2 will begin in November 2026, with the aim of confirming the superiority of LVT-001 in terms of the mucosal immune response.